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The relationship between liver and body mass is ex-
emplified by the precision with which the liver:body
mass ratio is restored after partial hepatic resection.
Nevertheless, the compartments, against which liver
mass is so exquisitely regulated, currently remain un-
defined. In the studies reported here, we investigated
the role of skeletal muscle mass in the regulation of
liver:body mass ratio and liver regeneration via the
analysis of myostatin-null mice, in which skeletal
muscle is hypertrophied. The results showed that
liver mass is comparable and liver:body mass signif-
icantly diminished in the null animals compared to
age-, sex-, and strain-matched controls. In association
with these findings, basal hepatic Akt signaling is
decreased, and the expression of the target genes of
the constitutive androstane receptor and the integrin-
linked kinase are dysregulated in the myostatin-null
mice. In addition, the baseline expression levels of the
regulators of the G1-S phase cell cycle progression in
liver are suppressed in the null mice. The initiation of
liver regeneration is not impaired in the null animals,
although it progresses toward the lower liver:bodymass
set point. The data show that skeletal muscle is not the
body component against which liver mass is positively
regulated, and thus they demonstrate a previously un-
recognized systemic compartmental specificity for the
regulation of liver:body mass ratio. (Am J Pathol 2012,
180:575–582; DOI: 10.1016/j.ajpath.2011.10.032)
Liver mass is regulated in specific proportion to body
mass. Such regulation is well-illustrated by the precision
with which the liver:body mass ratio is restored after
partial hepatic resection,1,2 and re-established after
small- or large-graft-for-recipient size liver transplanta-
tion3,4 in both clinical and experimental settings. Never-theless, the body mass components and compartments
against which liver mass is so precisely calibrated are
undefined. We have previously demonstrated that the
metabolic response to hepatic insufficiency regulates
liver regeneration. Those studies showed that following
partial hepatectomy, mice develop hypoglycemia,5 ca-
tabolize systemic fat stores,6 and transiently accumulate
triglyceride fat in the regenerating liver.7 We also showed
that liver regeneration is impaired by dextrose supple-
mentation,5 by strategies that suppress hepatic fat accu-
mulation,7 and in fatty liver dystrophy (fld) mice with genet-
ically-determined paucity of systemic adipose.6 These find-
ings suggest that catabolism of systemic fat stores might be
essential for liver regeneration. We have also observed that
extrahepatic lean tissue is catabolized after partial hepate-
ctomy or carbon tetrachloride (CCl4) administration,
6 and
that in each case the subsequent regenerative response is
associated with significant induction in skeletal muscle of
mRNA encoding the muscle-specific E3 ubiquitin protein
ligases MuRF1 and MafBx (D.A. Rudnick, unpublished ob-
servations).8 Those findings raise the possibility that muscle
mass could also contribute to the regulation of liver mass
and regeneration. Here, we investigated whether increased
skeletal muscle mass, as occurs in mice in which myostatin
expression is genetically disrupted,9,10 influences the reg-
ulation of liver:body mass or the hepatic regenerative re-
sponse to partial hepatectomy.
Materials and Methods
Animal Husbandry
Myostatin-null mice were generated as previously de-
scribed.9,10 Null, heterozygous, and wild-type mice,
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were maintained on 12 hours dark-light cycles with ad
libitum access to standard rodent chow and water.
Three-month-old male mice were used for all experi-
ments, except where otherwise specifically indicated.
Some mice were subjected to two-thirds partial hepa-
tectomy or sham surgery.5,6,11,12 Three or more ani-
mals were examined at each time point for each geno-
type. All experiments were approved by the Animal
Studies Committee at Washington University School of
Medicine and conducted in accordance with the insti-
tutional guidelines and the criteria outlined in the
“Guide for Care and Use of Laboratory Animals” (NIH
Publication No. 86-23).
Histology and Immunohistochemistry
Animals were given an intraperitoneal injection of 100
mg/kg 5-bromo-2=-deoxyuridine (BrdU) 1 hour before
sacrifice. Formalin-fixed, paraffin-embedded liver tissue
was stained with H&E for nuclear BrdU incorporation or
for TUNEL. Hepatocellular nuclear BrdU labeling and
mitoses were quantified by examining at least three ran-
dom400 fields and at least 300 cells and nuclei in each
tissue section.5,6,12,13 TUNEL staining was performed
with the In Situ Cell-Death Detection Kit (Roche, Mann-
heim, Germany) with DAPI as nuclear counterstain, ac-
cording to the manufacturer’s instructions. Hepatocellular
apoptosis was quantified as the percentage of TUNEL-pos-
itive cells in 10 to 20 high-powered (400) fields using a
fluorescent microscope (AxioVision, Zeiss, Thronwood,
NY). A TUNEL positive control was generated by pretreat-
ment with DNase I, according to the manufacturer’s instruc-
tions.
Gene Expression Analysis
Expression levels of specific genes of interest were de-
termined by semiquantitative, RT-qPCR as described
previously.5–7,12–14 Briefly, total liver RNA was extracted
using TRIzol (Invitrogen, Carlsbad, CA) and was reverse
transcribed to cDNA. An aliquot of cDNA was added to a
reaction mixture containing gene-specific forward and
reverse primers, deoxynucleotides, TaqDNA polymerase,
and SYBR Green (Stratagene, La Jolla, CA). Primers were
identified from the literature or using Primer Bank software
(http://pga.mgh.harvard.edu/primerbank/). Quantification
of mRNA expression was based on monitoring increased
SYBR Green fluorescence during exponential phase am-
plification in a real-time PCR MxPro3005 Machine (Strat-
agene) using the comparative threshold (Ct) method.15
The data were standardized to the expression of 2-
microglobulin.16–19 Specificity was verified for each gene
by confirmation of predicted product size and uniformity
using melt-curves and agarose-gel electrophoresis of the
PCR products, and by simultaneous analysis of a reac-
tion mixture containing all components except reverse
transcriptase. Primers used for these analyses included: Alb
(albumin): forward 5=-TTGCCGATGAGTCTGCCGCC-3=, re-
verse 5=-GGAGGTGCACATGGCCTCAGC-3=; Axin2: for-ward 5=-TGACTCTCCTTC-CAGATCCCA-3=, reverse 5=-
TGCCCACACTAGGCTGACA-3=; 2-microglobulin: forward
5=-TGGCTGCTTCTTTCGATTTCTG-3=, reverse 5=-CCA-
GAAAACCCCTCAAATTCAAG-3=; Car: forward 5=-GC-
CACTGTCCAGCCTGCAGG-3=, reverse 5=-TTTCTCTGC-
CCGCCGCTGTG-3=; Cdc25A: forward 5=-TCTGCACA-
TGGAAGAAGAGG-3=, reverse 5=-TTGCCATCAGTAGG-
CACAAT-3=; Cyclin D1: forward 5=-GAAGGAGACCAT-
TCCCTTGA-3=, reverse 5=-GTTCACCAGAAGCAGTTC-
CA-3=; Cyclin E: forward 5=-CTCGGGTGTTGTAGGT-
TGCT-3=, reverse 5=-CTGTTGGCTGACAGTGGAGA-3=;
Cyp2b10: forward 5=-TCCCCTGCCCCTCTTGGGGA-3=,
reverse 5=-CAGGCCTTGGTCCCAGGTGC-3=; Cyp3a11:
forward 5=-TGGAAACCTGGGTGCTCCTAGCA-3=, rev-
erse 5=-GGCAGAGGTTTGGGCCCAGG-3=; fructose bi-
sphosphatase 1 (Fbp1): forward 5=-TCTGTTTCGATC-
CCCTTGAT-3=, reverse 5=-GCTGCAGAGCATCCTTCTC-
3=; and Ilk: forward 5=-GGTGCGCTTGTGGCTGGACA-3=,
reverse 5=-CACCGCAGAGCGGCCTTCTC-3=.
Protein Expression
Proteins were quantified in whole tissue lysates, as
previously described.5,6,12,13 Briefly, lysates were sub-
jected to SDS-PAGE, followed by electrophoretic trans-
fer to nitrocellulose membrane. The filters were probed
with primary antibodies specific for each of the analyzed
proteins (total Akt, Ser 473 phospho-Akt, GSK3, Ser 9
phospho-GSK3, S6 kinase, Thr 421/Ser 424 phospho-S6
kinase, -catenin, and Ser 127 phospho-YAP (Cell Signal-
ing, Beverly, MA); glyceraldehydes-3-phosphate dehydro-
genase (GAPDH, Chemicon/Millipore, Temecula, CA); total
YAP (Santa Cruz Biotechnology, Santa Cruz, Ca) followed
by appropriate infrared fluorophore-conjugated secondary
antibodies (Li-COR Biosciences, Lincoln, NE). Reactivity
was quantified using the Odyssey Infrared Imaging System
(Li-COR Biosciences, Lincoln, NE).
Transaminase Measurement
Tissue alanine aminotransferase activity was deter-
mined using a lactate dehydrogenase coupled assay
supplemented with pyridoxal phosphate on the Cobas
c501 chemistry system (Roche Diagnostics, Indianap-
olis, IN).
Statistical Analysis
Data were analyzed using SigmaPlot version 8.02, Sig-
maStat version 3, and PASW Statistics version 18.0
(SPSS, Chicago, IL). Unpaired Student’s t-test for pair-
wise comparisons and analysis of variance for multiple
groups were used with significance () set at 0.05. Data
are reported as mean  SE.
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Liver Mass Is Not Increased, and the Liver:Body
Mass Ratio Is Reduced in Myostatin-Null Mice
First, we compared the liver:body mass ratio in 3-month-
old myostatin-null mice to that observed in strain-, age-,
and sex-matched wild-type and heterozygous control an-
imals. Myostatin is a transforming growth factor--super-
family member that negatively regulates muscle mass,
and myostatin-null mice have increased skeletal mus-
cle.9,10 Surprisingly, despite significantly greater muscle
mass, and therefore total body mass, in myostatin-null
mice compared to control animals, absolute liver weight
is comparable and the liver:body mass ratio is signifi-
cantly lower in the null mice (Figure 1, A–C). These data
indicate that liver mass and the liver:body mass ratio are
not increased in proportion to skeletal muscle mass in
adult mice. To assess for developmental effects on liver:
body mass regulation in these animals, 1-month-old male
myostatin null mice were also examined. These younger
mice also showed a higher body mass and lower liver:
body mass ratio compared to controls; however, the dif-
ferences were not as great as those seen in the older
animals and did not reach statistical significance (Figure
1D; P  0.15). These data indicate that the difference in
liver:body mass ratio between adult myostatin null mice
and controls develops as muscle mass increases in the
null animals. In an effort to assess whether liver function
in proportion to body mass is also reduced in myostatin
null mice, we quantified total liver tissue transaminase
activity in adult null and control mice. Previously we re-
ported that the magnitude of such tissue activity is pro-
portionate to liver mass.20 Similar analysis here showed
comparable total hepatic alanine transaminase activity
(data not shown) and a lower total hepatic tissue alanine
aminotransferase activity to body mass ratio in null versuscontrol animals (Figure 1E). These data show that liver
function assessed by this measure, as with liver mass, is
reduced relative to body mass in myostatin-null mice.
Hepatic Akt Activation Is Decreased in
Myostatin-Null Mice
The previously described data show that the liver:body
mass set point (ie, the “hepatostat”2) is lower in adult
myostatin-null mice than in age-, sex-, and strain-
matched control animals. One possible explanation for
this observation is that another body mass compartment
against which liver mass is regulated is also unchanged
in the myostatin-null mice. For example, systemic fat
mass has been reported to be comparable between
young adult myostatin-null mice and matched controls,9
and our previous studies implicate peripheral adipose
stores as an important determinant of normal liver regen-
eration.6,7 Alternatively, decreased liver:body weight ra-
tio in myostatin-null mice could be the result of signals
generated by or in response to increased muscle mass.
The observation that myostatin-null mice exhibit in-
creased insulin sensitivity and correspondingly de-
creased levels of circulating insulin21 suggests that acti-
vation of the insulin-responsive Akt signaling pathway
might be suppressed in myostatin-null mice. Activation of
this pathway is known to increase liver mass22 and reg-
ulate liver regeneration.23,24 Based on this consideration,
we compared basal hepatic Akt-dependent signaling be-
tween myostatin-null and control mice. The results
showed that the level of activated (serine 473 phosphor-
ylated) hepatic Akt is significantly lower in null mice than
in controls (Figure 2, A and B). Phosphorylation of
GSK3, which is a downstream target of the Akt kinase, is
also decreased in myostatin-null mouse liver compared
Figure 1. Decreased liver:body weight in myosta-
tin-null mice. A: Percent liver:body weight ratio in
3-month-old wild-type, heterozygous (Het), and null
mice (Male: *P  0.001 versus wild-type; P  0.002
versus Het; Female: **P  0.002 versus wild-type;
P 0.03 versus Het). B: Liver weight in 3-month-old
mice (no significant difference across groups). C:
Body weight in 3-month-old mice (Male: *P 0.001
versus wild-type; P  0.001 versus Het; Female:
**P  0.002 versus wild-type; P  0.02 versus Het).
D: Liver weight, body weight, and liver:body weight
ratio in 1-month-old male wild-type and null mice
(no significant difference across groups). E: Total he-
patic tissue alanine aminotransferase (ALT) activity:
body weight ratio in 3-month-old mice. *P  0.043
versus Het; *P 0.001 versus wild type; **P 0.005
versus wild type.to controls, whereas that of S6 kinase, another Akt target,
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(Figure 2, A and B). These findings show that the basal
level of Akt pathway activation is reduced in myostatin-
null mouse liver.
Comparison of Signals Implicated in Liver:Body
Mass Regulation between Myostatin-Null and
Control Mice
In addition to Akt, a number of other molecular pathways
have been implicated in the regulation of liver mass. For
example, pharmacological activation of the constitutive
androstane receptor (CAR)25,26 and genetic induction of
-catenin signaling27–30 promote increased liver mass.
Inactivation of the MST1/2 (Hippo) kinase cascade31 and
deletion of the integrin-linked kinase (ILK)32 also increase
liver mass. Therefore, we compared the activation state
and the expression of key components of each of these
pathways in livers from myostatin-null and control mice.First, the -catenin pathway was assessed. The results
showed comparable hepatic expression of -catenin pro-
tein (Figure 3A) and of the -catenin-target gene Axin2
(Figure 3B) in control and null mice. Analysis of the Hippo
kinase pathway also showed no effect of myostatin defi-
ciency on hepatic levels of the downstream target of this
cascade, (Ser 127) phosphorylated Yes association pro-
tein (YAP) (p-YAP, Figure 3C). p-YAP mediates the inhib-
itory effect of the mammalian Hippo ortholog MST1/2 on
liver size.33 Next, CAR signaling was examined. Expres-
sion of the CAR target gene Cyp2b10 is significantly
decreased in the nulls (Figure 3D). Car mRNA expression
is also modestly reduced in these animals, but this dif-
ference is not significant (Figure 3D) (P  0.1 versus wild
type). Hepatic expression of Ilk is significantly reduced in
the myostatin-null mice, and surprisingly mRNA expres-
sion of Cyp3a11, which is negatively regulated by ILK,32
is also reduced in the nulls (Figure 3D). Similarly, Albumin
and Fbp1 mRNA expression, which are also suppressed
. Analyses of signals implicated in liver:body mass regulation in myostatin-
e. Representative protein immunoblot and quantitative summary of -catenin
on standardized to glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
control (A), Axin2 mRNA expression (B), representative protein immunoblot
ntitative summary of Ser 127 phosphorylated, and total YAP expression (C),
, Cyp2b20, Ilk, Cyp3a11, Albumin, and fructose bisphosphatase 1 (Fbp1)
xpression in 3-month-old wild-type (WT), heterozygous (Het), and myosta-
ouse liver (D). *P 0.02 versus Het; **P 0.04 versus wild type; ***P 0.01
ild type.
Figure 2. Decreased hepatic AKT pathway activa-
tion in myostatin-null mice. Representative protein
immunoblot (A) and quantitative summary of basal
hepatic expression (B) of Ser 473 phosphorylated-
and total AKT, Ser 9 phosphorylated- and total
GSK3, and Thr 421/Ser 424 phosphorylated- and
total S6 kinase standardized to glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) loading control
in 3-month-old wild-type (WT), heterozygous (Het),
and myostatin-null mice. GAPDH is shown as load-
ing control. *P  0.02 versus wild type; **P  0.001
versus wild type; P  0.02 versus Het; ***P  0.09
versus wild type.Figure 3
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the myostatin knockouts (Figure 3D). These observations
demonstrate discordance between the regulation of ILK
expression and activity in myostatin-null mice, and more
importantly that basal hepatic ILK activity appears to be
increased in these animals (based on the diminished
expression of genes negatively regulated by ILK,32).
Taken together, these findings suggest that changes in
hepatic CAR or ILK activity contribute to the observed
alteration of the “hepatostat” in myostatin-null mice.
Regulators of G1-S Phase Cell Cycle
Progression Exhibit Reduced Expression in
Myostatin-Null Mice
Akt-, CAR-, and ILK-dependent signaling pathways might
influence liver:body mass through effects on proliferation,
size, or survival of liver cells; therefore, these parameters
were investigated in the livers of myostatin-null and con-
trol mice. We observed no detectable hepatocellular
BrdU incorporation or mitosis in control mice at baseline
(data not shown); thus, any inhibitory effect of myostatin
deficiency on hepatocellular proliferation is not demon-
strable using this approach. Cyclin D1 regulates cellular
proliferation and cell size,34 and its expression is regu-
lated by Akt34 and CAR26 activation. Therefore, we de-
termined hepatic expression of Cyclin D1 mRNA in myo-
statin-null and control mice, with the results showing
significantly lower levels in the null mice (Figure 4A).
mRNA abundances of Cyclin E and Cdc25A, which also
regulate G1-S progression, are lower in null animals as
Figure 5. Hepatocellular apoptosis in myostatin-null mice. Representative
positive cells (B) in liver sections from 3-month-old wild-type, heterozygous (Het), an
control liver section; no significant difference across groups).well (Figure 4A). Next, we estimated hepatocyte cell size
by hepatocellular nuclear density,35 and found no differ-
ence between null mice and controls (Figure 4B). Finally,
we investigated effects on cell survival by assessment of
hepatocellular apoptosis. Again, we observed no difference
in the very low basal rate of hepatocellular apoptosis in
livers from myostatin-null and control animals (Figure 5).
These data indicate that decreased liver:body mass is as-
sociated with lower expression of Cyclin D1, Cyclin E, and
Cdc25A, which could result from decreased basal activa-
tion of insulin-dependent hepatic Akt signaling or CAR in
myostatin-null mice. These data also show that hepatocel-
lular size and apoptosis are not altered in the null animals.
Liver Regeneration in Response to Partial
Hepatectomy Is Normally Induced in
Myostatin-Null Mice
Activation of Akt and increased expression of Cyclin D1,
Cyclin E, and Cdc25A occur during the hepatic regener-
ative response to partial hepatectomy.23,34 Therefore,
based on the results previously described, we compared
liver regeneration in myostatin-null and control mice next.
Analyses of hepatocellular proliferation showed compa-
rable hepatocellular BrdU incorporation 36 hours after
partial hepatectomy (the time of peak proliferation in wild-
type mice) in null and control animals (Figure 6, A and B).
Similarly, hepatocellular mitotic frequency 48 hours after
surgery (the time of peak mitotic progression during nor-
mal regeneration) is not affected in the null mice (Figure
6, A and B). We also assessed recovery of liver mass
Figure 4. Hepatic expression of cell cycle regula-
tors and determination of hepatocellular size in myo-
statin-null mice. Basal hepatic Cyclin D1, Cyclin E,
and Cdc25A mRNA expression (A) and hepatocellu-
lar nuclear density (number of nuclei per five 400
high-powered-fields [HPF], as a surrogate for hepa-
tocyte size) (B) in 3-month-old wild-type, heterozy-
gous, and myostatin-null mice. *P  0.1 versus wild
type; P  0.02 versus Het; **P  0.2 versus wild type;
P 0.05 versus Het; ***P 0.01 versus wild type, Het.
and DAPI-stained liver sections (A) and quantitative summary of TUNEL-TUNEL
d myostatin-null mice (20 micron bar shown in DAPI-stained TUNEL positive
580 Huang et al
AJP February 2012, Vol. 180, No. 2after partial hepatic resection. The results showed that the
liver:body weight ratio is lower in myostatin-null mice com-
pared to controls 7 days after the surgery; however, this
difference did not reach statistical significance (Figure 6C)
(P  0.1). These findings indicate that induction of liver
regeneration is not suppressed in myostatin-null mice, and
therefore that the initiation of the regenerative response is
not proportionate to the liver:body mass ratio. The data also
suggest that regeneration proceeds toward the lower liver:
body weight set point in the myostatin-null mice.
Discussion
Experimental analyses of liver regeneration portray the pre-
cision with which liver:body mass is regulated. The most
robust support for this concept comes from the rodent par-
tial hepatectomy model, in which regeneration is directly
proportionate to the magnitude of hepatic injury,6 and the
pre-hepatectomy liver:body mass ratio is restored before
termination of regeneration.1,2 Additional evidence of this
precise control comes from studies of experimental and
clinical liver transplantation, in which small-for-recipient-
size grafts enlarge and large organs become smaller
after transplantation, until the appropriate liver:body
mass ratio is ultimately attained.3,4 Finally, analyses of
mitogen-induced hepatomegaly show that withdrawal of
the mitogenic stimulus is also followed by restoration of
the liver:body mass set point.36 Nevertheless, the molec-
ular mechanisms that regulate this putative “hepatostat”
continue to be sought.2 Elucidation of this regulation re-
quires not only the characterization of the intrahepatic
signaling events involved, but also determination of thebody mass compartments against which liver mass is so
precisely maintained.
We have previously reported data demonstrating the
functional importance of the metabolic response to he-
patic insufficiency during experimental liver regenera-
tion.5–7,13 Those studies implicated catabolism of adi-
pose as essential for normal liver regeneration,6 but did
not establish if that requirement is based on adipose
stores as a source of metabolic fuel to support regener-
ation, lipid precursor for new membrane synthesis, a
specific signal that initiates the regenerative response
itself, or, perhaps, all of these. Our investigations also
demonstrated catabolism of systemic lean stores6 and
induction of the muscle-specific E3 ubiquitin ligases,
MuRF1 and MafBx, in both the partial hepatectomy and
carbon tetrachloride models of liver regeneration (D.A.
Rudnick, unpublished data8). Here, we extend on this
work by investigating the influence of skeletal muscle on
liver:body mass regulation and liver regeneration. Sur-
prisingly, liver mass is unchanged and liver:body mass is
significantly reduced in myostatin-null animals, which ex-
hibit significant skeletal muscle hypertrophy.9,10 This
finding indicates that the liver:body mass ratio set point
(ie, the “hepatostat”) is reduced in myostatin-null mice, a
conclusion supported by the diminished liver:body
weight ratio that we observed 1 week after partial hepa-
tectomy in these mice (Figure 6C).
We investigated several possible mechanisms to ex-
plain decreased liver:body mass in myostatin knockout
animals. Because these mice exhibit increased insulin
sensitivity and correspondingly diminished circulating
levels of insulin,21 we first examined the insulin sensitive
Figure 6. The hepatic regenerative response to partial
hepatectomy in myostatin-null mice. A: Immunohistochem-
ical analysis of hepatocellular BrdU incorporation 36 hours
after partial hepatectomy, andH&E staining of liver 48 hours
after partial hepatectomy (PH) (100 micron bar shown in
BrdU stained wild-type liver section). B: Quantitative sum-
mary of hepatocellular BrdU incorporation 36 and 48 hours
after partial hepatectomy and mitotic frequency (per 10
400 high-powered-fields) (HPF) 48 hours after partial hep-
atectomy in 3-month-old wild-type, heterozygous (Het),
and myostatin-null mice (no significant differences across
groups). C: Liver:body weight ratio at 72 hours and 7 days
after partial hepatectomy in myostatin-null mice and
heterozygous controls.Akt pathway. Our finding that the myostatin-null mice
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way, together with published data showing that Akt sig-
naling regulates liver mass and liver regeneration,22–24
suggest that differences in Akt pathway activity likely
contribute to the decreased liver:body mass ratio in these
animals. Our investigations did not identify differences
between null and control mice in either the -catenin or
Hippo kinase pathways. Each of these signaling cas-
cades also influences liver:body mass regulation,27–31
and recent analyses show that Hippo regulates -catenin
signaling.37 In contrast, both CAR and ILK signaling ap-
pear to be dysregulated in the myostatin-null mouse liver,
and interestingly these pathways have also been re-
ported to interact.38 These findings, together with our
data showing myostatin deficiency, does not impact he-
patocyte size or hepatocellular apoptosis, suggest that
the reduced liver:body mass in these animals is second-
ary to diminished basal hepatocellular proliferation. We
did not observe decreased proliferation directly because
basal rates of hepatocellular BrdU incorporation and mi-
tosis are undetectable in the wild-type controls in these
experiments (data not shown). However, hepatic expres-
sion of cyclin D1 and other regulators of cell cycle pro-
gression are significantly reduced in the myostatin-null
mice compared to controls. Because expression of cyclin
D1 by itself is sufficient to induce hepatocellular prolifer-
ation and increase liver size,39 the changes observed
here suggest a cyclin D1-dependent mechanism to ex-
plain the observed liver:body mass phenotype. More-
over, previously published data showing that Akt induces
cyclin D1 expression suggests that reduced hepatic Akt
activation is responsible for diminished cyclin D1 expres-
sion in these animals; however, it is important to note that
the data reported here do not directly demonstrate this
causal relationship.
As previously noted, our data demonstrate that abso-
lute liver mass is comparable (and liver:body mass re-
duced) in juvenile and adult, sex-matched myostatin-null
and control mice. This finding, together with the signifi-
cant increase in muscle mass, and thus total body mass,
in myostatin-null mice, accounts for the decreased liver:
body mass ratio in these animals. This observation poses
the following question: Is liver mass suppressed (below
the strain-defined “ideal” liver:body mass ratio) by in-
creased muscle mass, perhaps through the effects of
such increase on insulin sensitivity and Akt signaling,
hepatic ILK, and CAR activity, and expression of cell
cycle regulators? Alternatively, is the (as-yet undefined)
body compartment, against which liver mass and per-
haps hepatic -catenin expression and Hippo kinase
pathway signaling are normally regulated, also un-
changed in myostatin-null mice? It is intriguing to note
that young adult myostatin-null mice, which were studied
here, exhibit comparable amounts of body fat mass com-
pared to their strain matched wild-type counterparts,9 but
as these animals age (or if they are made leptin-deficient)
they accumulate less fat than their myostatin-expressing
counterparts.40 Thus, the data reported here provide ad-
ditional, albeit indirect, evidence in support of the previ-
ously suggested role for systemic adiposity in the regu-
lation of liver:body mass and liver regeneration6,7,41,42(ie, the liver mass:fat mass ratio appears to be preserved
in myostatin-null animals). Although another, unidentified
compartment against which liver mass is regulated may
also be unaffected in myostatin nulls, the data we present
here establish that skeletal muscle is not the body site
against which liver mass is positively regulated during
development or restored by regeneration following injury.
Thus, these findings demonstrate a previously unrecog-
nized systemic compartmental specificity that must exist
in liver:body mass regulation, and should prompt future
interrogation of sites other than skeletal muscle as the
master calibrator of hepatic size.
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